European Firms May Shift Away From China Due To Tougher Environment – European Chamber Of Commerce Survey
This article was originally published in PharmAsia News
Executive Summary
Survey finds lingering challenges and uncertainty despite – and sometimes because – of new government measures.
You may also be interested in...
Are China's Rising Labor Costs Good For Big Pharma?
HONG KONG - Rising labor costs are putting stress on manufacturing operations in China, but may prove to be a boon in the long term for companies focused on the world's fastest-growing domestic market
China Lays Out Requirements For Biosimilar Extrapolation
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
China Lays Out Requirements For Biosimilar Extrapolation
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
Need a specific report? 1000+ reports available
Buy Reports